← Leaderboards
Michael R Tadross
Duke University
$14,713,579
Attributed
$17,782,331
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.6M · FY2018–25$10M$7.5M$5M$2.5M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,782,331 · 8
By mechanism
R01$4,731,217 · 2
RF1$3,838,425 · 1
U01$3,336,521 · 1
DP2$2,412,000 · 1
R61$1,415,300 · 1
R33$1,335,788 · 1
Top collaborators
- Martha W Bagnall2 shared
- Adam D Douglass2 shared
- Timothy William Dunn2 shared
- Gregory Darin Field2 shared
- James Murray2 shared
- David Mclean1 shared
Most similar at Duke University
Same institution · by research overlap
- Marc G. Caron$32,189,154
- Veronica Galvin$226,480
- Timothy William Dunn$2,996,263
Others in their field
Other Emerging Leaders on “Behavioral”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Olwen Hahn · Brigham And Women'S Hospital$36,805,199
Research focus
BehavioralAnimalsCellsTechnologyAcutePharmacologyPharmaceutical PreparationsAffectReceptorExperimental StudyCell TypeNeuropharmacologySpecificityScienceDopamineBehaviorInsightMediatingOverexpressionMutationDoseFoundationsAxonIn Vivo
Grant awards (20)
Unmasking neuromodulatory control of locomotion$1,517,020
U01 · FY2025 · NS
DART.3-Revolutionizing Neuropsychiatric Treatment through Noninvasive, Programmable Cell-Type-Specific Neuropharmacology$1,380,473
R01 · FY2025 · MH · contact PI
High-throughput, high-resolution 3D measurement of ethologically relevant rodent behavior in a dynamic environment$350,440
R34 · FY2025 · DA
Unmasking neuromodulatory control of locomotion$1,819,501
U01 · FY2024 · NS
DART.3-Revolutionizing Neuropsychiatric Treatment through Noninvasive, Programmable Cell-Type-Specific Neuropharmacology$1,656,252
R01 · FY2024 · MH · contact PI
Interrogating the cholinergic basis of opioid use disorder$575,200
R33 · FY2024 · DA · contact PI
High-throughput, high-resolution 3D measurement of ethologically relevant rodent behavior in a dynamic environment$362,640
R34 · FY2024 · DA
Interrogating the cholinergic basis of opioid use disorder$85,672
R33 · FY2024 · DA · contact PI
Interrogating the cholinergic basis of opioid use disorder$589,244
R33 · FY2023 · DA · contact PI
Interrogating the cholinergic basis of opioid use disorder$85,672
R33 · FY2023 · DA · contact PI
Interrogating the cholinergic basis of opioid use disorder$460,811
R61 · FY2022 · DA · contact PI
Evaluating cell type-specific non-dopaminergics as a Parkinson's treatment paradigm$338,218
R01 · FY2022 · NS · contact PI
Interrogating the cholinergic basis of opioid use disorder$471,489
R61 · FY2021 · DA · contact PI
Evaluating cell type-specific non-dopaminergics as a Parkinson's treatment paradigm$338,739
R01 · FY2021 · NS · contact PI
Interrogating the cholinergic basis of opioid use disorder$483,000
R61 · FY2020 · DA · contact PI
Evaluating cell type-specific non-dopaminergics as a Parkinson's treatment paradigm$339,245
R01 · FY2020 · NS · contact PI
Evaluating cell type-specific non-dopaminergics as a Parkinson's treatment paradigm$339,736
R01 · FY2019 · NS · contact PI
DART2.0: comprehensive cell type-specific behavioral neuropharmacology$3,838,425
RF1 · FY2018 · MH · contact PI
Interrogating dynamics of whole-brain volumes with cell type-specific pharmacology$2,412,000
DP2 · FY2018 · MH · contact PI
Evaluating cell type-specific non-dopaminergics as a Parkinson's treatment paradigm$338,554
R01 · FY2018 · NS · contact PI